This invention relates to a single-liquid pharmaceutical composition for injection containing docetaxel. The composition includes (A) docetaxel and pharmaceutically acceptable salts thereof, (B) a surfactant selected from the group consisting of polysorbate, polyoxyethylene glycol ester and polyoxyethylene castor oil derivatives, (C) a solvent comprising anhydrous ethanol in a concentration range of 100 to 800 mg/ml, in an injectable solution, and (D) a pH adjuster of an amount suitable for adjusting the pH of the liquid composition to 5 or less. The composition may be directly diluted in a perfusion liquid even without the use of an intermediary dilute solution in case the composition is used for injectable preparations since the composition is in a single liquid phase. Furthermore, the composition is suitable for effective administration of docetaxel since the pharmaceutical stability of the composition is significantly improved.
